AOD-9604 in Dieciocho de Marzo — Fat Loss Peptide Research Guide
AOD-9604 research guide for Dieciocho de Marzo. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers trying to source AOD-9604 in Dieciocho de Marzo soon discover that local retail options are all but absent from local stores. The upside of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers more rigorous quality data than any local market ever offers. Separating quality AOD-9604 from the rest of the market requires three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the quality evaluation approach outlined here work regardless of your location.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Dieciocho de Marzo comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying AOD-9604: Quality Markers to Look For
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Warning signs in AOD-9604 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that omit endotoxin testing. Hold lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order AOD-9604 — ships to Dieciocho de Marzo
COA-verified · International tracking · Research grade
All use of AOD-9604 in Dieciocho de Marzo or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with bacteriostatic water. Verify the endotoxin level in your AOD-9604 batch COA before any protocol involving administration — look for results stated as EU/mg and compare against acceptable research limits for your application. PubMed and bioRxiv represent the most comprehensive research databases for AOD-9604 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
